Literature DB >> 15654219

Endoscopic Lothrop procedure: when should it be considered?

Lanny Garth Close1.   

Abstract

PURPOSE OF REVIEW: The endoscopic Lothrop procedure has proved to be an effective intranasal approach to the treatment of frontal sinus disorders. When successful, the operation re-establishes normal or near-normal frontal sinus function (especially physiologic evacuation of frontal sinus contents). Recently, several authors have proposed the use of this procedure for the treatment of several disease processes in addition to chronic frontal sinusitis. RECENT
FINDINGS: Although follow-up has been limited, the endoscopic Lothrop procedure has proved effective in the treatment of patients with the following: (1) failed prior endoscopic surgery, (2) frontal sinus mucocele, (3) frontoethmoid fractures, (4) failed osteoplastic flap frontal sinus obliteration, (5) resection of sinonasal neoplasms, and (6) removal of osteitic foci.
SUMMARY: When used by an experienced endoscopic surgeon in selected clinical settings, the endoscopic Lothrop procedure offer acceptable to excellent results with relatively low morbidity and with several advantages over more standard surgical approaches for the treatment of specific disease entities.

Entities:  

Mesh:

Year:  2005        PMID: 15654219     DOI: 10.1097/00020840-200502000-00015

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  2 in total

1.  Modified subtotal lothrop procedure for extended frontal sinus and anterior skull base access: a cadaveric feasibility study with clinical correlates.

Authors:  Jean Anderson Eloy; James K Liu; Osamah J Choudhry; Amy S Anstead; Belachew Tessema; Adam J Folbe; Roy R Casiano
Journal:  J Neurol Surg B Skull Base       Date:  2013-03-15

2.  The efficacy of extended Draf IIb procedure by partial nasal septectomy: long-term follow up.

Authors:  Ephraim Eviatar; Ahmed Taha; Haim Gavriel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-03       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.